Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$7.53 USD

7.53
124,923

-0.38 (-4.80%)

Updated Aug 25, 2026 03:42 PM ET

After-Market: $7.51 -0.02 (-0.27%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan

by Zacks Equity Research

Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.

Zacks Equity Research

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

by Zacks Equity Research

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.

Zacks Equity Research

Here's What Could Help Journey Medical Corporation (DERM) Maintain Its Recent Price Strength

by Zacks Equity Research

Journey Medical Corporation (DERM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

by Zacks Equity Research

Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.

Ahan Chakraborty headshot

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

by Ahan Chakraborty

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

Zacks Equity Research

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

by Zacks Equity Research

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Zacks Equity Research

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

by Zacks Equity Research

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Kinjel Shah headshot

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

by Kinjel Shah

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Zacks Equity Research

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

by Zacks Equity Research

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Zacks Equity Research

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

by Zacks Equity Research

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.